Baseline NT-proBNP and Biomarkers of Inflammation and Necrosis in Patients with ST-segment Elevation Myocardial Infarction: Insights from the APEX-AMI Trial
Overview
Authors
Affiliations
Coronary plaque rupture is associated with a systemic inflammatory response. The relationship between baseline N-terminal pro B-type natriuretic peptide (NT-proBNP), a prognostic marker in patients with acute coronary syndromes, and systemic inflammatory mediators in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) is not well described. Of 5,745 STEMI patients treated with primary PCI in the APEX-AMI trial, we evaluated the relationship between baseline NT-proBNP levels and baseline levels of inflammatory markers and markers of myonecrosis in a subset of 772 who were enrolled in a biomarker substudy. Spearman correlations (r (s)) were calculated between baseline NT-proBNP levels and a panel of ten systemic inflammatory biomarkers. Interleukin (IL)-6, a pro-inflammatory cytokine, was significantly positively correlated with NT-proBNP (r (s) = 0.317, P < 0.001). In a sensitivity analysis excluding all heart failure patients, the correlation between baseline IL-6 and NT-proBNP remained significant (n = 651, r (s) = 0.296, P < 0.001). A positive association was also observed with high sensitivity C-reactive protein (r (s) = 0.377, P < 0.001) and there was a weak negative correlation with the anti-inflammatory cytokine IL-10 (r (s) = -0.109, P = 0.003). No other significant correlations were observed among the other testes inflammatory cytokines and chemokines. In STEMI patients undergoing primary PCI, the pro-inflammatory cytokine IL-6 was modestly correlated with baseline NT-proBNP levels. This relationship remained significant in patients without heart failure. This finding is consistent with pre-clinical and clinical research suggesting that systemic inflammation may influence NT-proBNP expression independently of myocardial stretch.
Liu Z, Liu Z, Zhou H, Zhou Y, Xu X, Li Z Inflamm Res. 2023; 72(5):901-913.
PMID: 36933018 DOI: 10.1007/s00011-023-01708-0.
van Diepen S, Alemayehu W, Zheng Y, Theroux P, Newby L, Mahaffey K J Thromb Thrombolysis. 2016; 42(3):376-85.
PMID: 27324144 DOI: 10.1007/s11239-016-1390-z.
Dirajlal-Fargo S, Kinley B, Jiang Y, Longenecker C, Hileman C, Debanne S AIDS. 2015; 29(3):313-21.
PMID: 25686680 PMC: 4405026. DOI: 10.1097/QAD.0000000000000547.
IL-6 signalling in patients with acute ST-elevation myocardial infarction.
Ritschel V, Seljeflot I, Arnesen H, Halvorsen S, Weiss T, Eritsland J Results Immunol. 2014; 4:8-13.
PMID: 24707455 PMC: 3973821. DOI: 10.1016/j.rinim.2013.11.002.
Complement C3c as a biomarker in heart failure.
Frey A, Ertl G, Angermann C, Hofmann U, Stork S, Frantz S Mediators Inflamm. 2014; 2013:716902.
PMID: 24489446 PMC: 3892932. DOI: 10.1155/2013/716902.